此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Respiratory Pathogen Distribution During and After the COVID-19 Pandemic

2026年5月20日 更新者:Bekir Sami Uyanık、Hisar Intercontinental Hospital

Comparative Analysis of Respiratory Pathogens During and After the SARS-CoV-2 Pandemic: A Retrospective Multiplex PCR-Based Study

This retrospective observational study aims to evaluate changes in the prevalence and distribution of respiratory pathogens detected by multiplex respiratory polymerase chain reaction (PCR) testing during and after the SARS-CoV-2 pandemic. The study includes 537 patients presenting with respiratory infection symptoms at a tertiary care center. Patients were divided into pandemic-period and post-pandemic-period groups, and respiratory pathogen profiles were compared between the groups.

The study investigates the epidemiological impact of COVID-19-related public health measures on respiratory pathogen circulation patterns, including bacterial and viral respiratory infections. The findings may contribute to improved respiratory infection surveillance, diagnostic strategies, and post-pandemic public health preparedness.

研究概览

详细说明

The COVID-19 pandemic significantly altered the epidemiology of respiratory infections worldwide. Non-pharmaceutical interventions (NPIs), including mask use, social distancing, travel restrictions, enhanced hygiene measures, and lockdown policies, were implemented primarily to reduce SARS-CoV-2 transmission. However, these interventions also affected the circulation patterns of other respiratory pathogens.

Several studies have demonstrated substantial reductions in influenza, respiratory syncytial virus (RSV), and other respiratory viral infections during periods of strict public health measures. Following the relaxation of these interventions, many regions experienced re-emergence and altered seasonal patterns of respiratory pathogens. Continuous surveillance of respiratory infections has therefore become increasingly important for both clinical management and public health preparedness.

This retrospective observational cohort study aims to evaluate changes in respiratory pathogen prevalence during and after the SARS-CoV-2 pandemic using multiplex respiratory PCR testing data obtained from patients presenting with respiratory infection symptoms at a tertiary care center. A total of 537 patients were included and categorized into pandemic-period and post-pandemic-period groups.

Demographic characteristics and multiplex PCR results were analyzed and compared between the groups. Respiratory pathogens evaluated in the study included bacterial and viral agents such as Streptococcus pneumoniae, Haemophilus influenzae, Influenza A/B, SARS-CoV-2, RSV, Rhinovirus, Bocavirus, Parainfluenza virus, Coronavirus, and Metapneumovirus.

The study aims to contribute to understanding the long-term epidemiological effects of the COVID-19 pandemic and associated public health measures on respiratory pathogen distribution. In addition, the findings may support future infection surveillance strategies, diagnostic approaches, and healthcare preparedness in post-pandemic periods.

研究类型

观察性的

注册 (实际的)

537

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population consisted of patients presenting with respiratory infection symptoms who underwent multiplex respiratory polymerase chain reaction (PCR) testing at a tertiary care center during the pandemic and post-pandemic periods. Patients with complete demographic and laboratory data were included in the analysis.

描述

Inclusion Criteria:

  • Adults and/or pediatric patients presenting with respiratory infection symptoms
  • Patients who underwent multiplex respiratory PCR testing
  • Patients with complete demographic and laboratory records
  • Patients included during the defined pandemic or post-pandemic study periods

Exclusion Criteria:

  • Incomplete laboratory or demographic data
  • Duplicate test records from the same infection episode
  • Invalid or inconclusive PCR results
  • Patients without respiratory infection symptoms

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Pandemic Period Group
Patients presenting with respiratory infection symptoms who underwent multiplex respiratory PCR testing during the SARS-CoV-2 pandemic period.
Post-Pandemic Period Group
Patients presenting with respiratory infection symptoms who underwent multiplex respiratory PCR testing during the post-pandemic normalization period.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in the prevalence of respiratory pathogens between the pandemic and post-pandemic periods
大体时间:Retrospectively assessed at the time of respiratory PCR testing during the study periods. Pandemic period: March 2020 - May 2023 Post-pandemic period: June 2023 - December 202
The primary outcome is the difference in detection rates of respiratory pathogens identified by multiplex respiratory PCR testing between the SARS-CoV-2 pandemic period and the post-pandemic period.
Retrospectively assessed at the time of respiratory PCR testing during the study periods. Pandemic period: March 2020 - May 2023 Post-pandemic period: June 2023 - December 202

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年1月1日

初级完成 (实际的)

2024年12月30日

研究完成 (实际的)

2024年12月30日

研究注册日期

首次提交

2026年5月13日

首先提交符合 QC 标准的

2026年5月20日

首次发布 (实际的)

2026年5月22日

研究记录更新

最后更新发布 (实际的)

2026年5月22日

上次提交的符合 QC 标准的更新

2026年5月20日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data (IPD) will not be shared because this retrospective study contains hospital-based patient data, and sharing such data may compromise patient confidentiality and institutional data protection policies.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅